Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): Surveillance Review, Program Announcement PAR-04-106, 54925 [05-18527]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 180 / Monday, September 19, 2005 / Notices
Investment Limited, and New York
Global Partners, L.P., all of New York,
New York, is revised to read as follows:
A. Federal Reserve Bank of Atlanta
(Andre Anderson, Vice President) 1000
Peachtree Street, N.E., Atlanta, Georgia
30303:
1. York Capital Management, L.P.,
York Investment Limited, York Global
Value Partners, L.P., York Global Value
Holdings, LLC, Dinan Management, LLC,
York Offshore Holdings, Limited, Dinan
Management, L.P., Dinan Management
Corporation, and James G. Dinan
(collectively, ‘‘York’’), all of New York,
New York, and York Global Value
Holdings, L.P., York Global Value
Holdings, LLC and James G. Dinan,
individually and on behalf of the York
group, to acquire up to 24.9 percent of
the voting shares of PanAmerican
Bancorp, Miami, Florida, and thereby
indirectly acquire voting shares of
PanAmerican Bank, Miami, Florida.
Comments on this application must
be received by October 4, 2005.
Board of Governors of the Federal Reserve
System, September 14, 2005.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 05–18597 Filed 9–16–05; 8:45 am]
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
Federal Open Market Committee;
Domestic Policy Directive of August 9,
2005
In accordance with § 271.25 of its
rules regarding availability of
information (12 CFR part 271), there is
set forth below the domestic policy
directive issued by the Federal Open
Market Committee at its meeting held
on August 9, 2005.1
The Federal Open Market Committee
seeks monetary and financial conditions
that will foster price stability and
promote sustainable growth in output.
To further its long-run objectives, the
Committee in the immediate future
seeks conditions in reserve markets
consistent with increasing the federal
funds rate to an average of around 31⁄2
percent.
The vote encompassed approval of the
paragraph below for inclusion in the
statement to be released shortly after the
meeting:
1 Copies of the Minutes of the Federal Open
Market Committee Meeting on August 9, 2005,
which includes the domestic policy directive issued
at the meeting, are available upon request to the
Board of Governors of the Federal Reserve System,
Washington, DC 20551. The minutes are published
in the Federal Reserve Bulletin and in the Board’s
annual report.
VerDate Aug<31>2005
15:48 Sep 16, 2005
Jkt 205001
‘‘The Committee perceives that, with
appropriate monetary policy action, the
upside and downside risks to the
attainment of both sustainable growth
and price stability should be kept
roughly equal. With underlying
inflation expected to be contained, the
Committee believes that policy
accommodation can be removed at a
pace that is likely to be measured.
Nonetheless, the Committee will
respond to changes in economic
prospects as needed to fulfill its
obligation to maintain price stability.’’
both CDC and the Agency for Toxic
Substances and Disease Registry.
By order of the Federal Open Market
Committee, September 6, 2005.
Vincent R. Reinhart,
Secretary, Federal Open Market Committee.
[FR Doc. 05–18559 Filed 9–16–05; 8:45 am]
54925
Food and Drug Administration
Dated: September 13, 2005.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–18527 Filed 9–16–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. 2005N–0262]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Submission of Chemistry,
Manufacturing, and Controls
Information in a New Drug Application
Under the New Pharmaceutical Quality
Assessment System; Extension of
Application and Comment Deadlines
AGENCY:
Food and Drug Administration,
HHS.
Centers for Disease Control and
Prevention
ACTION:
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panels (SEP): Surveillance
Review, Program Announcement PAR–
04–106
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
extension in the deadlines for
submitting requests to participate in and
comment on a pilot program involving
the submission of chemistry,
manufacturing, and controls (CMC)
information consistent with the new
pharmaceutical quality assessment
system.
DATES: Submit written requests to
participate in the pilot program by
March 31, 2006. Submit eligible new
drug applications (NDAs) by March 31,
2007. Submit written or electronic
comments on the pilot program by
March 31, 2007.
ADDRESSES: Submit written requests to
participate in the pilot program and
comments on the pilot program to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Submit electronic requests to
participate in and comments on the
pilot program to https://www.fda.gov/
dockets/ecomments.
FOR FURTHER INFORMATION CONTACT:
Michael Folkendt, Center for Drug
Evaluation and Research (HFD–800),
Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857,
301–827–5918, e-mail:
folkendtm@cder.fda.gov.
SUPPLEMENTARY INFORMATION:
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
Name: Disease, Disability, and Injury
Prevention and Control Special Emphasis
Panel (SEP): Surveillance Review, Program
Announcement PAR–04–106.
Times and Dates: 8 a.m.–5 p.m., November
2, 2005 (Closed), 8 a.m.–5 p.m., November 3,
2005 (Closed).
Place: Marriott Inner Harbor at Camden
Yard, 110 South Eutaw Street, Baltimore, MD
21201, Telephone Number 410.962.0202.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of applications received in
response to: Surveillance Review, Program
Announcement PAR–04–106.
Contact Person For More Information:
Steve Olenchock, PhD, Scientific Review
Administrator, National Institute for
Occupational Safety and Health, CDC, 1095
Willowdale Road, Morgantown, WV 26506,
Telephone 304.285.6127.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Notice to extend application
and comment deadlines.
I. Background
In the Federal Register of July 14,
2005 (70 FR 40719), FDA announced
E:\FR\FM\19SEN1.SGM
19SEN1
]]>Agencies
[Federal Register Volume 70, Number 180 (Monday, September 19, 2005)]
[Notices]
[Page 54925]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-18527]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panels (SEP): Surveillance Review, Program Announcement PAR-
04-106
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting:
Name: Disease, Disability, and Injury Prevention and Control
Special Emphasis Panel (SEP): Surveillance Review, Program
Announcement PAR-04-106.
Times and Dates: 8 a.m.-5 p.m., November 2, 2005 (Closed), 8
a.m.-5 p.m., November 3, 2005 (Closed).
Place: Marriott Inner Harbor at Camden Yard, 110 South Eutaw
Street, Baltimore, MD 21201, Telephone Number 410.962.0202.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: The meeting will include the review,
discussion, and evaluation of applications received in response to:
Surveillance Review, Program Announcement PAR-04-106.
Contact Person For More Information: Steve Olenchock, PhD,
Scientific Review Administrator, National Institute for Occupational
Safety and Health, CDC, 1095 Willowdale Road, Morgantown, WV 26506,
Telephone 304.285.6127.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: September 13, 2005.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 05-18527 Filed 9-16-05; 8:45 am]
BILLING CODE 4163-18-P
